No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac DiseaseJoseph A. Murray, Richard A. Krause, Tsung‐Teh Wu et al.|Gastroenterology|2016Cited by 137
Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group studyChristophe Cellier, Ralph Raymond, Gerd Bouma et al.|The Lancet. Gastroenterology & hepatology|2019Cited by 101